| 2258 | Humans |
| 1791 | Antibodies, Monoclonal, Humanized |
| 1147 | Female |
| 1060 | Arthritis, Rheumatoid |
| 1009 | Antirheumatic Agents |
| 992 | Male |
| 813 | Middle Aged |
| 794 | Treatment Outcome |
| 659 | Adult |
| 550 | Aged |
| 512 | Antibodies, Monoclonal |
| 487 | Interleukin-6 |
| 458 | Receptors, Interleukin-6 |
| 313 | Tumor Necrosis Factor-alpha |
| 283 | Methotrexate |
| 263 | Animals |
| 255 | Biological Products |
| 249 | Drug Therapy, Combination |
| 224 | Immunosuppressive Agents |
| 221 | Severity of Illness Index |
| 183 | Retrospective Studies |
| 176 | Arthritis, Juvenile |
| 174 | Glucocorticoids |
| 171 | Adolescent |
| 170 | Child |
| 169 | Abatacept |
| 168 | Remission Induction |
| 167 | Rituximab |
| 162 | Young Adult |
| 143 | Time Factors |
| 140 | Etanercept |
| 138 | Infliximab |
| 136 | Adalimumab |
| 134 | Biomarkers |
| 118 | Signal Transduction |
| 112 | Giant Cell Arteritis |
| 108 | Follow-Up Studies |
| 105 | Randomized Controlled Trials as Topic |
| 104 | Cytokines |
| 99 | Prospective Studies |
| 99 | Castleman Disease |
| 93 | Double-Blind Method |
| 93 | Disease Progression |
| 92 | Inflammation |
| 92 | Clinical Trials as Topic |
| 92 | Aged, 80 and over |
| 89 | Child, Preschool |
| 87 | Takayasu Arteritis |
| 87 | C-Reactive Protein |
| 87 | Anti-Inflammatory Agents |
| 86 | Still's Disease, Adult-Onset |
| 86 | Mice |
| 86 | Immunoglobulin G |
| 85 | Risk Factors |
| 81 | Drug Administration Schedule |
| 80 | Immunologic Factors |
| 76 | Biological Therapy |
| 74 | Japan |
| 73 | Dose-Response Relationship, Drug |
| 71 | Antibodies, Monoclonal, Murine-Derived |
| 67 | Registries |
| 67 | Immunoconjugates |
| 65 | Receptors, Tumor Necrosis Factor |
| 63 | Interleukin 1 Receptor Antagonist Protein |
| 63 | Adrenal Cortex Hormones |
| 62 | Prognosis |
| 60 | Recurrence |
| 59 | Cohort Studies |
| 58 | Molecular Targeted Therapy |
| 57 | Immunotherapy |
| 55 | Biological Factors |
| 54 | Rheumatic Diseases |
| 54 | Prednisone |
| 54 | Drug Resistance |
| 49 | Tomography, X-Ray Computed |
| 49 | Infusions, Intravenous |
| 48 | Diagnosis, Differential |
| 47 | Uveitis |
| 47 | Treatment Failure |
| 45 | Amyloidosis |
| 43 | Magnetic Resonance Imaging |
| 43 | Drug Substitution |
| 43 | Cell Line, Tumor |
| 42 | Incidence |
| 41 | United States |
| 41 | T-Lymphocytes |
| 41 | Cell Proliferation |
| 40 | STAT3 Transcription Factor |
| 40 | Risk Assessment |
| 40 | Quality of Life |
| 40 | Joints |
| 39 | Prednisolone |
| 39 | Injections, Subcutaneous |
| 39 | Disease Models, Animal |
| 39 | Certolizumab Pegol |
| 39 | Biopsy |
| 38 | Polymyalgia Rheumatica |
| 37 | Inflammation Mediators |
| 37 | Autoimmune Diseases |
| 36 | Predictive Value of Tests |
| 35 | Neoplasms |
| 34 | Syndrome |
| 34 | Receptors, Antigen, T-Cell |
| 34 | Anti-Inflammatory Agents, Non-Steroidal |
| 33 | Case-Control Studies |
| 33 | Behcet Syndrome |
| 32 | Cost-Benefit Analysis |
| 32 | Chronic Disease |
| 31 | Spondylitis, Ankylosing |
| 31 | Pyrroles |
| 31 | Pyrimidines |
| 31 | Fever |
| 31 | Cardiovascular Diseases |
| 31 | Blood Sedimentation |
| 30 | Scleroderma, Systemic |
| 30 | Piperidines |
| 29 | Radiography |
| 29 | Lupus Erythematosus, Systemic |
| 29 | Arthritis, Psoriatic |
| 28 | Opportunistic Infections |
| 27 | Neuromyelitis Optica |
| 27 | Immunotherapy, Adoptive |
| 26 | Pregnancy |
| 26 | Immunocompromised Host |
| 26 | Disease Management |
| 26 | Cells, Cultured |
| 25 | T-Lymphocytes, Regulatory |
| 25 | Polychondritis, Relapsing |
| 25 | Infant |
| 25 | Evidence-Based Medicine |
| 25 | Drug Monitoring |
| 24 | Rheumatology |
| 24 | Proportional Hazards Models |
| 24 | Pilot Projects |
| 24 | Infections |
| 24 | Edema |
| 24 | B-Lymphocytes |
| 24 | Antineoplastic Agents |
| 23 | Psoriasis |
| 23 | Practice Guidelines as Topic |
| 23 | Graves Ophthalmopathy |
| 23 | Cyclosporine |
| 23 | Cyclophosphamide |
| 23 | Autoantibodies |
| 23 | Arthritis |
| 23 | Antigens, CD19 |
| 22 | Vasculitis |
| 22 | Serum Amyloid A Protein |
| 22 | Phenotype |
| 22 | Mice, Inbred C57BL |
| 22 | Methylprednisolone |
| 22 | Lung Diseases, Interstitial |
| 22 | Enzyme-Linked Immunosorbent Assay |
| 22 | Combined Modality Therapy |
| 21 | Outcome Assessment, Health Care |
| 21 | Neutrophils |
| 21 | Longitudinal Studies |
| 21 | Kaplan-Meier Estimate |
| 21 | Drug Design |
| 20 | Xenograft Model Antitumor Assays |
| 20 | Visual Acuity |
| 20 | Surveys and Questionnaires |
| 20 | Macrophage Activation Syndrome |
| 20 | Leflunomide |
| 20 | Interleukin-1 |
| 20 | Health Status |
| 19 | Synovial Membrane |
| 19 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| 19 | Positron-Emission Tomography |
| 19 | Gene Expression Regulation |
| 19 | Comorbidity |
| 19 | Antineoplastic Combined Chemotherapy Protocols |
| 18 | Vascular Endothelial Growth Factor A |
| 18 | Th17 Cells |
| 18 | Steroids |
| 18 | Retreatment |
| 18 | Receptors, Chimeric Antigen |
| 18 | Rats |
| 18 | Leukocytes, Mononuclear |
| 18 | Immunohistochemistry |
| 18 | Drug-Related Side Effects and Adverse Reactions |
| 18 | Drug Interactions |
| 18 | Apoptosis |
| 17 | Withholding Treatment |
| 17 | Tomography, Optical Coherence |
| 17 | Thrombocytopenia |
| 17 | Monocytes |
| 17 | Matrix Metalloproteinase 3 |
| 17 | Injections, Intravenous |
| 17 | Graft vs Host Disease |
| 17 | Europe |
| 17 | Databases, Factual |
| 16 | Spondylarthritis |
| 16 | RNA, Messenger |
| 16 | Protein Kinase Inhibitors |
| 16 | Pregnancy Complications |
| 16 | Models, Biological |
| 16 | Lung |
| 16 | Logistic Models |
| 16 | Drug Eruptions |
| 16 | Disability Evaluation |
| 16 | Cross-Sectional Studies |
| 16 | Anti-Bacterial Agents |
| 15 | Ultrasonography |
| 15 | Synovitis |
| 15 | Skin |
| 15 | Risk |
| 15 | Polymorphism, Single Nucleotide |
| 15 | Polyethylene Glycols |
| 15 | Network Meta-Analysis |
| 15 | Multivariate Analysis |
| 15 | Italy |
| 15 | France |
| 15 | Crohn Disease |
| 15 | Clinical Trials, Phase III as Topic |
| 14 | Ustekinumab |
| 14 | Recombinant Fusion Proteins |
| 14 | Odds Ratio |
| 14 | Magnetic Resonance Angiography |
| 14 | Lymphohistiocytosis, Hemophagocytic |
| 14 | Liver |
| 14 | Interleukin-1beta |
| 14 | Immunoglobulin Fab Fragments |
| 14 | Gene Expression Regulation, Neoplastic |
| 14 | Flow Cytometry |
| 14 | Drug Hypersensitivity |
| 14 | Drug Delivery Systems |
| 14 | Drug Approval |
| 14 | Colchicine |
| 14 | Cell Movement |
| 14 | Arthritis, Experimental |
| 14 | Antiviral Agents |
| 14 | Antibodies |
| 14 | Algorithms |
| 14 | Administration, Intravenous |
| 13 | Tumor Necrosis Factor Inhibitors |
| 13 | Tacrolimus |
| 13 | Sweden |
| 13 | Mycophenolic Acid |
| 13 | Mutation |
| 13 | Lymph Nodes |
| 13 | Isoxazoles |
| 13 | Interleukin-17 |
| 13 | Induction Chemotherapy |
| 13 | Hydroxychloroquine |
| 13 | Hematopoietic Stem Cell Transplantation |
| 13 | Germany |
| 13 | Gene Expression |
| 13 | Familial Mediterranean Fever |
| 13 | DNA, Viral |
| 13 | Cell Line |
| 13 | Bayes Theorem |
| 12 | Virus Activation |
| 12 | United Kingdom |
| 12 | Ultrasonography, Doppler |
| 12 | Tumor Cells, Cultured |
| 12 | Reproducibility of Results |
| 12 | Quality-Adjusted Life Years |
| 12 | Pneumonia, Viral |
| 12 | Neutropenia |
| 12 | Multiple Myeloma |
| 12 | Mice, SCID |
| 12 | Macrophages |
| 12 | Graft Rejection |
| 12 | Genetic Predisposition to Disease |
| 12 | Fatal Outcome |
| 12 | Cytokine Receptor gp130 |
| 12 | Cell Survival |
| 12 | CD4-Positive T-Lymphocytes |
| 12 | Aortitis |
| 12 | Anemia |
| 11 | T-Lymphocyte Subsets |
| 11 | Prevalence |
| 11 | Phosphorylation |
| 11 | Peptides |
| 11 | Patient Selection |
| 11 | Pandemics |
| 11 | Myositis |
| 11 | Multiple Sclerosis |
| 11 | Mice, Inbred BALB C |
| 11 | Medication Adherence |
| 11 | Lymphocyte Activation |
| 11 | Lipids |
| 11 | Interleukins |
| 11 | Coronavirus Infections |
| 11 | Carcinoma, Squamous Cell |
| 11 | Betacoronavirus |
| 11 | Azathioprine |
| 11 | Antibodies, Anti-Idiotypic |
| 11 | Age of Onset |
| 10 | Viral Load |
| 10 | Sulfasalazine |
| 10 | Rheumatoid Factor |
| 10 | Renal Insufficiency |
| 10 | Regression Analysis |
| 10 | Recombinant Proteins |
| 10 | Precision Medicine |
| 10 | Pneumonia |
| 10 | Off-Label Use |
| 10 | Macular Edema |
| 10 | Leukocyte Count |
| 10 | Kidney |
| 10 | Inflammatory Bowel Diseases |
| 10 | Immunoglobulins, Intravenous |
| 10 | Graft Survival |
| 10 | Fibrosis |
| 10 | Bone Density |
| 10 | Body Mass Index |
| 10 | Biosimilar Pharmaceuticals |
| 10 | Antineoplastic Agents, Immunological |
| 10 | Antigens, CD |
| 10 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
| 10 | Age Factors |
| 9 | Wound Healing |
| 9 | Transplantation, Homologous |
| 9 | Survival Rate |
| 9 | Skin Diseases |
| 9 | Sjogren's Syndrome |
| 9 | Sensitivity and Specificity |
| 9 | Reverse Transcriptase Polymerase Chain Reaction |
| 9 | Real-Time Polymerase Chain Reaction |
| 9 | Rats, Sprague-Dawley |
| 9 | RANK Ligand |
| 9 | Product Surveillance, Postmarketing |
| 9 | Pregnancy Outcome |
| 9 | Peptides, Cyclic |
| 9 | Peptide Fragments |
| 9 | Pain |
| 9 | Pain Measurement |
| 9 | Oxidative Stress |
| 9 | Ovarian Neoplasms |
| 9 | Multimodal Imaging |
| 9 | Lung Neoplasms |
| 9 | Kidney Diseases |
| 9 | Interferon-gamma |
| 9 | Hereditary Autoinflammatory Diseases |
| 9 | Hematologic Neoplasms |
| 9 | Health Care Costs |
| 9 | Gene Expression Profiling |
| 9 | Fatigue |
| 9 | Drug Resistance, Neoplasm |
| 9 | Drug Discovery |
| 9 | Drug Costs |
| 9 | Cytokine Release Syndrome |
| 9 | Collagen Type I |
| 9 | Coculture Techniques |
| 9 | Cholesterol |
| 9 | Cell Differentiation |
| 9 | Atherosclerosis |
| 9 | Arthrography |
| 8 | Up-Regulation |
| 8 | United States Food and Drug Administration |
| 8 | Survival Analysis |
| 8 | Spondylarthropathies |
| 8 | Spain |
| 8 | Skin Neoplasms |
| 8 | Secondary Prevention |
| 8 | Salvage Therapy |
| 8 | ROC Curve |
| 8 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
| 8 | Plasma Cells |
| 8 | Patient Acuity |
| 8 | Neurotoxicity Syndromes |
| 8 | Neoplasm Metastasis |
| 8 | NF-kappa B |
| 8 | Mice, Nude |
| 8 | Medication Therapy Management |
| 8 | Macrophage Activation |
| 8 | Macaca fascicularis |
| 8 | Lipoprotein(a) |
| 8 | Kidney Transplantation |
| 8 | Insulin Resistance |
| 8 | Immunophenotyping |
| 8 | Herpesvirus 4, Human |
| 8 | Herpes Zoster |
| 8 | Hepcidins |
| 8 | Hepatitis B |
| 8 | Hepatitis B virus |
| 8 | Hand Joints |
| 8 | Forecasting |
| 8 | Fluorodeoxyglucose F18 |
| 8 | Drug Evaluation, Preclinical |
| 8 | Down-Regulation |
| 8 | Desensitization, Immunologic |
| 8 | Dendritic Cells |
| 8 | Chemical and Drug Induced Liver Injury |
| 8 | Cartilage, Articular |
| 8 | Bone and Bones |
| 8 | Bone Marrow |
| 8 | Blotting, Western |
| 8 | Biomarkers, Tumor |
| 8 | Asthma |
| 8 | Asian Continental Ancestry Group |
| 8 | Arthralgia |
| 8 | Antibodies, Bispecific |
| 7 | Vitamin D |
| 7 | Tuberculosis |
| 7 | Transplantation, Heterologous |
| 7 | Transforming Growth Factor beta |
| 7 | Transcriptome |
| 7 | Stroke |
| 7 | Sex Factors |
| 7 | Sepsis |
| 7 | Scleroderma, Localized |
| 7 | Sarcoidosis |
| 7 | Recovery of Function |
| 7 | Primary Myelofibrosis |
| 7 | Patient Safety |
| 7 | Oligonucleotide Array Sequence Analysis |
| 7 | Observational Studies as Topic |
| 7 | Neoplastic Stem Cells |
| 7 | Myocardial Infarction |
| 7 | Mice, Inbred DBA |
| 7 | Lymphocytes |
| 7 | Lung Diseases |
| 7 | Intercellular Signaling Peptides and Proteins |
| 7 | Insulin |
| 7 | Influenza, Human |
| 7 | Infant, Newborn |
| 7 | Immunomodulation |
| 7 | Immune System Diseases |
| 7 | Hypertension, Pulmonary |
| 7 | Hospitalization |
| 7 | Half-Life |
| 7 | Genotype |
| 7 | Fluorescein Angiography |
| 7 | Fibroblasts |
| 7 | Fibrinogen |
| 7 | Endothelial Cells |
| 7 | Early Diagnosis |
| 7 | Drugs, Investigational |
| 7 | Drug Tolerance |
| 7 | Dermatomyositis |
| 7 | Contraindications |
| 7 | Comparative Effectiveness Research |
| 7 | Communicable Diseases |
| 7 | Clinical Decision-Making |
| 7 | Chemokines |
| 7 | Arthritis, Infectious |
| 7 | Aquaporin 4 |
| 7 | Aorta |
| 7 | Antibodies, Antineutrophil Cytoplasmic |
| 7 | Administration, Oral |
| 6 | Wrist Joint |
| 6 | Thrombosis |
| 6 | Th2 Cells |
| 6 | Systemic Vasculitis |
| 6 | Respiratory Tract Infections |
| 6 | Radiopharmaceuticals |
| 6 | Postoperative Complications |
| 6 | Positron Emission Tomography Computed Tomography |
| 6 | Osteocalcin |
| 6 | Observer Variation |
| 6 | Non-ST Elevated Myocardial Infarction |
| 6 | Models, Immunological |
| 6 | Mice, Transgenic |
| 6 | Mice, Knockout |
| 6 | Metacarpophalangeal Joint |
| 6 | Melanoma |
| 6 | Maintenance Chemotherapy |
| 6 | MAP Kinase Signaling System |
| 6 | Lymphocyte Depletion |
| 6 | Lymphocyte Count |
| 6 | Kidney Failure, Chronic |
| 6 | Janus Kinases |
| 6 | Intestinal Perforation |
| 6 | Interleukin-2 Receptor alpha Subunit |
| 6 | Interleukin-18 |
| 6 | Influenza Vaccines |
| 6 | Immunosuppression |
| 6 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
| 6 | Hepatitis B, Chronic |
| 6 | Hemoglobins |
| 6 | Head and Neck Neoplasms |
| 6 | Genome-Wide Association Study |
| 6 | Gastrointestinal Diseases |
| 6 | Eye Diseases |
| 6 | Exanthema |
| 6 | Endothelium, Vascular |
| 6 | Dyspnea |
| 6 | Disease-Free Survival |
| 6 | Diphosphonates |
| 6 | Depression |
| 6 | DNA Mutational Analysis |
| 6 | China |
| 6 | Cartilage |
| 6 | Brazil |
| 6 | Brain |
| 6 | Bone Resorption |
| 6 | Autoimmunity |
| 6 | Area Under Curve |
| 6 | Antigens, CD20 |
| 6 | Antibody Formation |
| 6 | Antibodies, Antinuclear |
| 5 | Vaccination |
| 5 | Ulcer |
| 5 | Turkey |
| 5 | Thalidomide |
| 5 | Th1 Cells |
| 5 | Temporal Arteries |
